Skip to content
Research Article Open access CC BY 4.0

Development and Validation of New Analytical LC-MS/MS Method for the Estimation of Antidiabetic Drugs Ertugliflozin and Sitagliptin in Combined Pharmaceutical Dosage form

Suleman S. Khoja, Laxman J. Patel

Journal of Pharmaceutical Research International · pp. 194–204 · Published 2 Jun 2021

10.9734/jpri/2021/v33i30A31631

Abstract

Ertugliflozin and Sitagliptin is combination of Antidiabetic drug in tablet Steglujan 15 mg/100 mg film-coated tablets®, a member Antidiabetic drug, is a recent drug developed by Merck Sharp and Dohme Company for the treatment of Type 2 diabetes. Ertugliflozin and Sitagliptin can be used alone or in combination therapy. A highly sensitive, precise and accurate Liquid Chromatography with mass spectrometry (LC-MS/MS) method is developed and validated for the determination of Ertugliflozin and Sitagliptin in combined formulation. Chromatographic separation was carried out on Phenomenex Gemini, C18, (150 × 4.6 mm,5 μm) column. Isocratic method was based on 0.1% formic acid: acetonitrile (10:90, v/vas mobile phase, column temperature at 40°C and flow rate at 0.6 mL/minuteswere utilized. The mass spectrometer was operated under multiple reactions monitoring (MRM) mode using electrospray ionization by monitoring the transition pair (precursor to product ion) of m/z 437.10-328.95in the positive mode for Ertugliflozin and transition pair (precursor to product ion) of m/z 408.10-234.95 in the positive mode for Sitagliptin. The method was found linear in the concentration range of 15 to 450 ng/mL and 100–3000 ng/mL for Ertugliflozin and Sitagliptin respectively. The optimized method was validated according to the International Conference on Harmonization (ICH) and FDA guidelines. The developed method was found suitable for the quantitation of Ertugliflozin and Sitagliptin in Pharmaceutical dosage form.

Ertugliflozin sitagliptin LC-MS/MS validation assay mass spectrometry

Cited by 25

Recent applications of liquid chromatography tandem mass spectrometry at various stages of drug development

S. Gagare, V. Thorat, A. Jain · Future Journal of Pharmaceutical Sciences · 2026

Advances in analytical strategies for fixed-dose gliflozin combinations: A comprehensive evaluation

S. Sridevi, N. Harikrishnan · Current Pharmaceutical Analysis · 2026

An Overview on Analytical Method Development and Validation for Ertugliflozin in Bulk and Pharmaceutical Dosage form

Priyanka M. Sagar, S. Mankar, S. B. Dighe · Asian Journal of Pharmaceutical Analysis · 2023

Identification, isolation, and structural characterization of novel forced degradation products of Ertugliflozin using advanced analytical techniques

Suresh Salakolusu, Naresh Kumar Katari, Ganapavarapu Veera Raghava Sharma · Scientific Reports · 2023

Showing 9 of 25 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

10

Page views

0

PDF downloads

1

Outbound clicks

25

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.